Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

Exclusion criteria

• ✕. Combined with other connective tissue diseases;
• ✕. Involvement of important organs: heart (individuals with more severe heart disease, such as angina, myocardial infarction, heart failure, and arrhythmias), kidney (eGFR \< 15 ml/min/1.73m2), liver (ALT\>3×ULN, AST\>3×ULN, TBIL \>1.5×ULN), lung (FVC\<50% predicted or hemoglobin-corrected DLCO\<40% predicted), hematologic (leukocyte \< 2.5×109/L, neutrophil count \<1.0×109/L, HGB\<60g/L), etc.;
• ✕. Abnormal hepatitis B or hepatitis C test indicating active infection or chronic infection, including positive HBsAg or HBcAb test and positive hepatitis C antibody;
• ✕. Have active tuberculosis or latent tuberculosis;
• ✕. Human immunodeficiency virus (HIV) serology positivity or known history of HIV infection;
• ✕. Presence of any known serious active infection (including bacterial, viral, fungal, etc.), including those requiring hospitalization or intravenous antibiotic therapy within 4 weeks prior to screening and oral antibiotic therapy within 2 weeks prior to screening; Those who have various chronic infections and are currently receiving corresponding treatment, such as pneumocystosis, cytomegalovirus, herpes zoster, atypical mycobacteria, etc.;
• ✕. Patients with primary or secondary immunodeficiency;
• ✕. IgA deficiency (\<10 mg/dL) or IgG deficiency (\<400 mg/dL);